Last reviewed · How we verify
GDC-9545 Capsule, Fasted: Treatment B
At a glance
| Generic name | GDC-9545 Capsule, Fasted: Treatment B |
|---|---|
| Also known as | Giredestrant, RO7197597, RG6171 |
| Sponsor | Genentech, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Dry eye
- Constipation
- Costochondritis
- Flushing
- Skin abrasion
- Blood creatine phosphokinase increased
- Headache
- Upper-airway cough syndrome
Key clinical trials
- Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-9545 Following a Single Oral Dose (Part 1) and to Evaluate the Absolute and Relative Bioavailability of Oral Capsule Formulations of GDC-9545 (Part 2) in Healthy Female Subjects of Non-Childbearing Potential (PHASE1)
- Evaluation of the Relative Bioavailability and Food Effect of GDC-9545 in Healthy Females of Non-Childbearing Potential (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GDC-9545 Capsule, Fasted: Treatment B CI brief — competitive landscape report
- GDC-9545 Capsule, Fasted: Treatment B updates RSS · CI watch RSS
- Genentech, Inc. portfolio CI